-
Aptamer and WuXi AppTec Form Research Partnership
contractpharma
July 23, 2021
?Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, have entered a research collaboration to identify new Optimer-enabled therapeutics.
-
Aptamer Group Collaborates with PinotBio
contractpharma
June 03, 2021
?Aptamer Group Limited, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for ...
-
Aptamer Extends Collaboration with AstraZeneca
contractpharma
March 08, 2021
Aptamer Group, the developer of Optimer reagents and therapeutics, has extended their current agreement with AstraZeneca.
-
Aptamer Group, AstraZeneca extend collaboration to explore next-gen drug delivery approaches
expresspharma
March 05, 2021
The companies will evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
